🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
In this single arm, open label, phase 2 trial, operable patients with stage...
Status
Unknown
Location
Yantai Yuhuangding Hospital
Start Date
2022-08-04
Trial ID
NCT05800756
Treatments Being Tested
This is an open label, phase III study evaluating the efficacy and safety o...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2023-05-06
Trial ID
NCT05841381
Treatments Being Tested
This study is a single-center, single-arm, prospective phase II clinical st...
Status
Completed
Location
Tianjin Cancer Hospital
Start Date
2021-01-01
Trial ID
NCT04903652
Treatments Being Tested
This study is a one-arm, open, phase II clinical study, and the study subje...
Status
Recruiting
Location
Peking University Cancer Hospital
Start Date
2020-07
Trial ID
NCT04481932
Treatments Being Tested
The purpose of this study is to establish a prospective, single-center plat...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Start Date
2022-11-01
Trial ID
NCT05582499
Treatments Being Tested
The purpose of this study is to identify the highest tolerable dose of pyro...
Status
Unknown
Location
Multiple Locations
Start Date
2019-08-15
Trial ID
NCT03997539
Treatments Being Tested
The objective of this study is to evaluate the efficacy of combination of p...
Status
Unknown
Location
Shusen Wang
Start Date
2020-12-04
Trial ID
NCT04334330
Treatments Being Tested
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in c...
Status
Unknown
Location
Shanghai Changzheng Hospital
Start Date
2019-07-01
Trial ID
NCT03843749
Treatments Being Tested
This study is a randomized, open-label, phase II study, comparing the effic...
Status
Unknown
Location
Multiple Locations
Start Date
2019-06-01
Trial ID
NCT03910712
Treatments Being Tested
Trastuzumab resistance, which is a common therapeutic challenge in HER2 pos...
Status
Unknown
Location
Fudan University Shanghai Cancer Center
Start Date
2019-06-26
Trial ID
NCT04001621
Treatments Being Tested